B세포림프종의 임상적 악성도 표지자로서 혈청 Thymidine Kinase 1의 유용성
Usefulness of Serum Thymidine Kinase 1 as a Biomarker for Aggressive Clinical Behavior in B-cell Lymphoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
배경: Thymidine kinase 1 (TK1)은 세포 주기의 중요한 조절 효소로 암세포의 증식 시에 증가하는 것으로 알려져 있으며, 현재까지 혈액종양과 다양한 고형암에서 진단 또는 치료 후 모니터링과 예후 예측에 중요한 표지자로 보고되고 있다. 본 연구에서는 한국인에서 혈청 TK1 정량분석을 통하여 건강인의 혈청 TK1 참고치를 설정하고자 하였으며 B세포림프종 환자를 대상으로 임상적 악성도 표지자로서 혈청 TK1 검사의 유용성을 평가하고자 하였다. 방법: 72명의 B세포림프종 환자와 143명의 건강대조군의 혈청검체에서 화학발광면역측정법으로 혈청 TK1 농도를 측정하였다. 건강대조군에서 혈청 TK1의 참고치를 설정하였고, 환자군과 건강대조군에서 측정된 혈청 TK1 결과를 이용해 ROC 분석을 통한 기준치를 구하여 상대적으로 높은 혈청 TK1 정량값과 B세포림프종의 임상 지표들과의 상관성을 비교하였다. 결과: 전체 건강대조군의 혈청 TK1의 95 percentile에 따른 참고범위는 5.4-21.8 U/L였다. B세포림프종 환자군과 건강대조군의 혈청 TK1 수치 비교에서 평균±표준편차는 각각 40.6±68.5 U/L와 11.8±4.4 U/L로 나타났으며 두 그룹 간에 유의한 차이를 보였다(P<0.001). ROC 분석 후, 혈청 TK1 수치 15.2 U/L를 이용하였을 때 민감도 59.7%, 특이도 83.2%, AUC 0.73을 보여 B세포림프종 환자를 선별할 수 있는 기준치로 설정하였다. 상대적으로 높은 혈청 TK1 수치(≥15.2 U/L)는 병기, 골수침범, IPI 점수, LD 수치, 낮은 Hb (<12 g/dL), 림프구 수와 상관성이 있는 것으로 나타났다. 결론: B세포림프종 환자에서 측정되는 혈청 TK1 수치는 B세포림프종의 임상적 악성도 표지자로서 유용하게 사용될 수 있을 것이다.
Abstract
Background: The cell cycle-dependent enzyme thymidine kinase 1 (TK1) is known to increase during cancer cell proliferation and has been reported as a prognostic marker for various hematologic malignancies and solid tumors. This study aimed to determine the reference interval in Korean healthy controls and to evaluate the usefulness of TK1 as a biomarker for aggressive clinical behavior in B-cell lymphoma patients. Methods: We enrolled 72 previously untreated patients with B-cell lymphoma and 143 healthy controls. Serum TK1 levels were measured by chemiluminescence immunoassay (Liaison®, DiaSorin, USA). We established the reference intervals in healthy controls. The diagnostic performance of serum TK1 was studied using receiver operating characteristic (ROC) analysis, and the correlation between the cutoff level for serum TK1 and clinical characteristics of B-cell lymphoma was evaluated. Results: The reference range (95th percentile) of serum TK1 in healthy controls was 5.4-21.8 U/L. There was a clear difference in TK1 levels between patients with B-cell lymphoma and healthy controls (40.6±68.5 vs. 11.8±4.4 U/L, P<0.001). The area under the curve of serum TK1 for the diagnosis of B-cell lymphoma was 0.73 (cutoff, 15.2 U/L; sensitivity, 59.7%; specificity, 83.2%). An increased TK1 level (≥15.2 U/L) correlated with the advanced clinical stage (P<0.001), bone marrow involvement (P=0.013), international prognostic index score (P=0.001), lactate dehydrogenase level (P=0.001), low Hb level (<12 g/dL) (P=0.028), and lymphocyte count (P=0.023). Conclusions: The serum TK1 level could serve as a useful biomarker for aggressive clinical behavior in B-cell lymphoma patients.
참고문헌 (21)
- Sherley JL, "Regulation of human thymidine kinase during the cell cycle", J Biol Chem, 15(263), pp.8350~8358 (1988)
- Munch-Petersen B, "Enzymatic regulation of cytosolic thymidine kinase 1 and mitochondrial thymidine kinase 2: a mini review", Nucleosides Nucleotides Nucleic Acids, 29, pp.363~369 (2010)
- Aufderklamm S, "Thymidine kinase and cancer monitoring", Cancer Lett, 316, pp.6~10 (2012)
- Gronowitz JS, "The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin’s lymphoma", Br J Cancer, 47, pp.487~495 (1983)
- Rehn S, "A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma", Hematol Oncol, 9, pp.287~298 (1991)
- Hallek M, "Activity of serum thymidine kinase in non-Hodgkin lym phoma: relationship to other prognostic factors", Klin Wochenschr, 66, pp.718~723 (1988)
- Hallek M, "Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin’s lymphoma and a broad range of potential clinical applications", Ann Hematol, 65, pp.1~5 (1992)
- Ellims PH, "Prognostic relevance of thymidine kinase isozymes in adult non- Hodgkin’s lymphoma", Blood, 58, pp.926~930 (1981)
- Pan ZL, "Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients", J Cancer Res Clin Oncol, 136, pp.1193~1199 (2010)
- Sadamori N, "Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia", Br J Haematol, 90, pp.100~105 (1995)
- O’Neill KL, "Buckwalter MR, Murray BK. Thymidine kinase: diagnostic and prognostic potential", Expert Rev Mol Diagn, 1, pp.428~433 (2001)
- Svobodova S, "Prognostic importance of thymidine kinase in colorectal and breast cancer", Anticancer Res, 27, pp.1907~1909 (2007)
- O’Neill KL, "Serum thymidine kinase levels in cancer patients", Ir J Med Sci, 155, pp.272~274 (1986)
- The Korean Society of Hematology, "the Korean Society of Hematology. Hematology", pp.381~394 (2011), PanMun
- Ke PY, "Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex", cyclosome-CDH1-mediated pathway, 2004, pp.24, 514~526
- Chen Y, "Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings", Int J Clin Oncol, 15, pp.359~368 (2010)
- Di Raimondo F, "Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine", Ann Oncol, 12, pp.621~625 (2001)
- Konoplev SN, "High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia", Am J Clin Pathol, 134, pp.472~477 (2010)
- Szánthó E, "Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia", PLoS One, 9, pp.e91647~ (2014)
- Xu XH, "Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy", Mol Med Rep, 1, pp.705~711 (2008)
- Chen ZH, "Serological thymidine kinase 1 is a biomarker for early detection of tumours-- a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay", Sensors, 11, pp.11064~11080 (2011)